Get your patient on Zingo - Lidocaine Hydrochloride Monohydrate powder (Lidocaine Hydrochloride Monohydrate)
Zingo - Lidocaine Hydrochloride Monohydrate powder prescribing information
------------------ RECENT MAJOR CHANGES-------------------
Warnings and Precautions, Methemoglobinemia (5.1) 11/2018
------------------INDICATIONS AND USAGE-------------------
- ZINGO is an amide local anesthetic indicated for use on intact skin to provide local analgesia prior to venipuncture or peripheral intravenous cannulation in children 3–18 years of age. (1)
- ZINGO is indicated for use on intact skin to provide topical local analgesia prior to venipuncture in adults. (1)
Important Limitations :
For use on intact skin only (1, 2)
For external use only (5)
---------------DOSAGE AND ADMINISTRATION---------------
- Apply one ZINGO (0.5 mg lidocaine hydrochloride monohydrate) to the site planned for venipuncture or intravenous cannulation, one to three minutes prior to needle insertion. (2.1)
- Perform the procedure within 10 minutes after ZINGO administration. (2)
- Use ZINGO only on intact skin. (2)
-------------DOSAGE FORMS AND STRENGTHS-------------
ZINGO is a sterile, single-use, powder intradermal injection system containing 0.5 mg lidocaine hydrochloride monohydrate. (3) ZINGO utilizes a helium-powered delivery system. (11)
8 USE IN SPECIFIC POPULATIONS
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Risk Summary Available published data and decades of clinical use with lidocaine in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Lidocaine is not detectable systemically following intradermal administration [see Clinical Pharmacology (12.3)], and maternal use is not expected to result in fetal exposure to the drug. Lidocaine has been previously tested for reproductive toxicity in animal studies. The following ratios are based on the assumption that the applied dose is completely absorbed through the skin. In an animal reproduction study, pregnant rats administered lidocaine, containing 1:100,000 epinephrine, injected into the masseter muscle of the jaw or into the gum of the lower jaw at a dose of 6 mg/kg at 120-fold the single dermal administration (SDA) of 0.5 mg lidocaine on Gestation Day 11 resulted in developmental delays in neonatal behavior among offspring. In another animal reproduction study, no developmental toxicities were observed in rats administered lidocaine by subcutaneous route at doses up to 1200-fold the SDA or in rabbits up to 600-fold the SDA (see Data).
The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies carry some risk of birth defects, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Data Animal Data Lidocaine was not teratogenic in rats given subcutaneous doses up to 60 mg/kg [360 mg/m2 or 1200-fold the single dermal administration (SDA) of 0.5 mg lidocaine in a 60 kg individual (0.3 mg/m2)] or in rabbits up to 15 mg/kg (180 mg/m2 or 600-fold the SDA) during the period of organogenesis. In a published study, lidocaine administered to pregnant rats by continuous subcutaneous infusion during the period of organogenesis at doses of 100, 250, and 500 mg/kg/day, did not produce any structural abnormalities, but did result in lower fetal weights at 500 mg/kg/day (3000 mg/m2 or 10,000-fold the SDA on a mg/m2 basis) in the absence of maternal toxicity. Lidocaine, containing 1:100,000 epinephrine, at a dose of 6 mg/kg (36 mg/m2 or 120-fold the SDA) injected into the masseter muscle of the jaw or into the gum of the lower jaw of Long-Evans hooded pregnant rats on Gestation Day 11 led to developmental delays in neonatal behavior among offspring. Developmental delays were observed for negative geotaxis, static righting reflex, visual discrimination response,sensitivity and response to thermal and electrical shock stimuli, and water maze acquisition. The developmental delays of the neonatal animals were transient with responses becoming comparable to untreated animals later in life. The clinical relevance of the animal data is uncertain.
8.2 Lactation
Risk Summary Published data report the presence of lidocaine and its metabolites in human milk in low amounts following parenteral administration, along with poor oral bioavailability. There are no data on the effect of lidocaine on the breastfed infant or the effect on milk production. There are no detectable plasma concentrations of lidocaine after subdermal administration of ZINGO; therefore, breastfeeding is not expected to result in exposure of the child to lidocaine [see Clinical Pharmacology (12.3)]. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZINGO and any potential adverse effects on the breastfed child from ZINGO or from the underlying maternal condition.
8.4 Pediatric Use
Safety and effectiveness in pediatric patients below the age of 3 years have not been established.
8.5 Geriatric Use
Of the 693 patients evaluated in a Phase 3 randomized, double blind, sham-placebo-controlled trial in adults, 17% were of 65 and over. The safety and effectiveness of ZINGO in geriatric patients were similar to that of ZINGO in adults under 65 years of age.
---------------------CONTRAINDICATIONS---------------------
ZINGO is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type. (4)
---------------WARNINGS AND PRECAUTIONS---------------
- Methemoglobinemia : Cases of methemoglobinemia have been reported in association with local anesthetic use. (5.1)
- Use on intact skin only (2.1, 5)
- Avoid contact with the eye (2.1, 5)
- Do not use if device is dropped or the pouch is damaged or torn (2.1)
- Patients with bleeding tendencies or platelet disorders could have a higher risk of superficial dermal bleeding (5)
---------------------ADVERSE REACTIONS---------------------
The most common adverse reactions (>5%) are skin reactions at the site of administration: erythema, petechiae, edema, and pruritus (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact 7T Pharma, LLC, at 1-800-941-2848 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
See 17 for PATIENT COUNSELING INFORMATION.
Revised: December 2025
7 DRUG INTERACTIONS
Patients who are administered local anesthetics are at increased risk of developing methemoglobinemia when concurrently exposed to the following drugs, which could include other local anesthetics:
Examples of Drugs Associated with Methemoglobinemia:
Class | Examples |
Nitrates/Nitrites | nitric oxide, nitroglycerin, nitroprusside, nitrous oxide |
Local anesthetics | articaine, benzocaine, bupivacaine, lidocaine, mepivacaine, prilocaine, procaine, ropivacaine, tetracaine |
Antineoplastic agents | cyclophosphamide, flutamide, hydroxyurea, ifosfamide, rasburicase |
Antibiotics | dapsone, nitrofurantoin, para-aminosalicylic acid, sulfonamides |
Antimalarials | chloroquine, primaquine |
Anticonvulsants | phenobarbital, phenytoin, sodium valproate, |
Other drugs | acetaminophen, metoclopramide, quinine, sulfasalazine |
11 DESCRIPTION
ZINGO ® (lidocaine hydrochloride monohydrate) powder intradermal injection system contains 0.5 mg of sterile lidocaine hydrochloride monohydrate.
The chemical name is 2-diethylamino-2',6'-acetoxylidide, monohydrochloride, monohydrate. The molecular formula is C 14 H 22 N 2 O · HCl · H 2 O with a molecular weight of 288.8 Da. Lidocaine hydrochloride monohydrate, a local anesthetic of the amide class, has the following structural formula:
Lidocaine hydrochloride monohydrate is freely soluble in water, soluble in alcohol and chloroform, insoluble in ether, and melts at around 74–79°C.
ZINGO is a ready-to-use, sterile, single-use, disposable, needle-free delivery system. ZINGO consists of the following components: a drug reservoir cassette filled with 0.5 mg lidocaine hydrochloride monohydrate as a powder with a nominal particle size of 40 µm, a pressurized helium gas cylinder, and a safety interlock. The safety interlock prevents inadvertent actuation of the device. Once ZINGO is pressed against the skin, the interlock is released, allowing the button to be depressed to actuate the device. A sound similar to that of a popping balloon is emitted at the time ZINGO is actuated.
12 CLINICAL PHARMACOLOGY
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
ZINGO delivers lidocaine hydrochloride monohydrate into the dermis. Lidocaine is an amide-type local anesthetic agent that blocks sodium ion channels required for the initiation and conduction of neuronal impulses, resulting in local anesthesia.
12.2 Pharmacodynamics
ZINGO provides local dermal analgesia within 1–3 minutes of application. Analgesia diminishes within 10 minutes of treatment.
12.3 Pharmacokinetics
Absorption
A single dose of ZINGO in adults did not produce detectable plasma concentrations of lidocaine (limit of quantitation 5 ng/mL) in any subject tested (n = 38).
Application of ZINGO to broken or inflamed skin, or multiple ZINGO applications, could result in systemic plasma levels of lidocaine that could produce systemic toxicity.
Distribution
When lidocaine is administered intravenously to healthy volunteers, the steady-state volume of distribution is approximately 0.8 to 1.3 L/kg. At much higher plasma concentrations (1 to 4 mcg/mL of free base) than those found following application of ZINGO, the plasma protein binding of lidocaine is concentration dependent. Lidocaine crosses the placental and blood brain barriers, presumably by passive diffusion. CNS toxicity may typically be observed around 5000 ng/mL of lidocaine; however a small number of patients reportedly may show signs of toxicity at approximately 1000 ng/mL.
Metabolism
It is not known if lidocaine is metabolized in the skin. Lidocaine is metabolized rapidly by the liver to a number of metabolites including monoethylglycinexylidide (MEGX) and glycinexylidide (GX), both of which have pharmacologic activity similar to, but less potent than that of lidocaine. The major metabolic pathway of lidocaine, sequential N-deethylation to monoethylglycinexylidide (MEGX) and glycinexylidide (GX), is primarily mediated by CYP1A2 with a minor role of CYP3A4. The metabolite, 2,6-xylidine, has unknown pharmacologic activity. Following intravenous administration of lidocaine, MEGX and GX concentrations in serum range from 11% to 36% and from 5% to 11% of lidocaine concentrations, respectively. Serum concentrations of MEGX are about one-third the serum lidocaine concentrations.
Elimination
The half-life of lidocaine elimination from the plasma following intravenous administration is approximately 1.8 hours. Lidocaine and its metabolites are excreted by the kidneys. More than 98% of an absorbed dose of lidocaine can be recovered in the urine as metabolites or parent drug. Less than 10% of lidocaine is excreted unchanged in adults, and approximately 20% is excreted unchanged in neonates. The systemic clearance is approximately 8–10 mL/min/kg. During intravenous studies, the elimination half-life of lidocaine was statistically significantly longer in elderly patients (2.5 hours) than in younger patients (1.5 hours).
13 NONCLINICAL TOXICOLOGY
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
Carcinogenesis
Long-term studies in animals have not been performed to evaluate the carcinogenic potential of lidocaine.
Mutagenesis
No mutagenic potential of lidocaine was demonstrated in the in vitro Ames Bacterial Reverse Mutation Assay, the in vitro chromosome aberration assay using Chinese hamster ovary cells, and the in vivo mouse micronucleus assay.
Impairment of Fertility
ZINGO was not formally evaluated for effects on fertility. Significant systemic exposure to lidocaine is not expected under recommended conditions of use of ZINGO, as lidocaine levels were below the limit of detection in human studies. Lidocaine has been previously tested in animal studies for effects on fertility, however. The following ratios are based on the assumption that the applied dose is completely absorbed through the skin.
Lidocaine did not affect fertility in female rats when given via continuous subcutaneous infusion via osmotic minipumps up to doses of 250 mg/kg/day [1500 mg/m 2 or 5000-fold higher than the SDA of 0.5 mg lidocaine in a 60 kg individual (0.3 mg/m 2 )]. Although lidocaine treatment of male rats increased the copulatory interval and led to a dose-related decreased homogenization resistant sperm head count, daily sperm production, and spermatogenic efficiency, the treatment did not affect overall fertility in male rats when given subcutaneous doses up to 60 mg/kg (360 mg/m 2 or 1200-fold the SDA).
14 CLINICAL STUDIES
Efficacy in Adults
The efficacy of ZINGO in adults was evaluated in a randomized, double-blind, parallel-arm, sham-placebo controlled trial in which adult patients who required a venipuncture or peripheral venous cannulation received either ZINGO or a sham placebo device.
Patients were treated with ZINGO or a placebo device at the antecubital fossa or back of the hand, between one and three minutes prior to venipuncture or peripheral venous cannulation. Measurements of pain were made immediately following the procedure. Efficacy was measured using a continuous 100 mm visual analogue scale ranging from 0 (“no pain”) to 100 (“worst possible pain”).
Many of the patients had chronic medical problems such as depression, hypertension, hypothyroidism, and hyperlipidemia and over one fourth of the population may have been at higher than average risk of dermal bleeding due to use of concomitant medications such as NSAIDs, aspirin, and corticosteroids.
Treatment with active drug resulted in less pain compared with placebo (see Table 1).
However, efficacy was primarily seen in patients undergoing venipuncture at the antecubital fossa, while patients undergoing cannulation at the back of the hand did not demonstrate a difference between active and sham administrations.
Efficacy in Pediatric Patients
The efficacy of ZINGO in patients 3–18 years of age was evaluated in two randomized, double-blind, parallel-arm, sham-placebo controlled trials in which pediatric patients received either ZINGO or a sham placebo device.
The overall patient population consisted of healthy pediatric patients as well as those with acute and chronic medical conditions (i.e., diabetes, asthma, seizure disorder, juvenile rheumatoid arthritis and renal or hepatic transplantation) ages 3–18 years. All patients required peripheral venipuncture or intravenous cannulation as part of their clinical care.
Two efficacy trials (Studies 1 and 2) were conducted during which patients were treated with ZINGO or a placebo device at the back of hand or antecubital fossa, between one and three minutes prior to venipuncture or peripheral venous cannulation. Measurements of pain were made immediately following the venous procedure. Efficacy was measured using a modified version of the Wong-Baker FACES pain rating scale [a categorical 6-point scale containing 6 faces ranging from 0 (“no hurt”) to 5 (“hurts worst”)].
In both studies, treatment with active drug resulted in less pain, from venipuncture or peripheral IV cannulation, compared with placebo (See Table 2).
16 HOW SUPPLIED/STORAGE AND HANDLING
NDC 61388-123 ZINGO ® (lidocaine hydrochloride monohydrate) powder intradermal injection system contains 0.5 mg of sterile lidocaine hydrochloride monohydrate. ZINGO ® is a single-dose device packaged in an individual clear pouch. Twelve pouched devices are placed in labeled cartons.
Cartons are stored at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
2.1 Instructions for Use
Prepare the Treatment Site and Device :
Examine the treatment site to ensure that the skin is intact. Clean the site, according to standard practice.
Visually inspect the pouch. Do not use if the pouch has been torn, or damaged or if the device has been dropped.
Tear open the pouch using the notch provided (Figure 1a). Remove ZINGO from the pouch, being careful not to touch the purple outlet (open end) to avoid contamination (Figure 1b).
Position ZINGO : Grip ZINGO and place on the application site, with one hand, as illustrated in Figure 2, or with both hands, as shown in Figure 3.
Ensure that the patient’s treatment site is supported to prevent movement. Seal the purple ZINGO outlet against the patient’s skin. Hold the device perpendicular to the skin, making sure that your thumb can reach the green start button.
Avoid gaps between the skin and the ZINGO outlet, like the one illustrated in Figure 4, as gaps will impede drug delivery.
Release the Safety Interlock : Apply adequate downward pressure to release the safety interlock, while maintaining the seal between ZINGO and the skin.
ZINGO is ready for administration when the green start button has moved into the upward position, as illustrated in Figure 5a.
ZINGO cannot be actuated without releasing the internal safety interlock, as illustrated in Figure 5b.
Administer ZINGO : While maintaining downward pressure, administer the dose by pressing the green start button, as illustrated in Figure 6. Do not move ZINGO during administration. Actuation is accompanied by a “popping” sound, indicating that the dose has been discharged.
Remove ZINGO : Remove ZINGO from the application site and dispose.
Begin Procedure : Start the venipuncture or intravenous cannulation procedure 1–3 minutes after ZINGO administration.
12.1 Mechanism of Action
ZINGO delivers lidocaine hydrochloride monohydrate into the dermis. Lidocaine is an amide-type local anesthetic agent that blocks sodium ion channels required for the initiation and conduction of neuronal impulses, resulting in local anesthesia.
